Use of apc analogue for wound healing

Abstract

The invention relates to wound repair and healing, particularly to dermal or cutaneous wounds including but not limited to acute and chronic wounds, burns and ulcers.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 15 / 304,433, filed Oct. 14, 2016, which is a filing under 35 U.S.C. 371 of PCT / AU2015 / 050177, filed Apr. 16, 2015, which claims priority from Australian Patent Application No. 2014902900, filed Jul. 25, 2014, and Australian Patent Application No. 2014901397, filed Apr. 16, 2014. These prior applications are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]The invention relates to wound repair and healing, particularly to dermal or cutaneous wounds including but not limited to acute and chronic wounds, burns and ulcers.BACKGROUND OF THE INVENTION[0003]Reference to any prior art in the specification is not an acknowledgment or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be understood, regarded as relevant, and / or combined with other pieces of pri...

AI Technical Summary

Benefits of technology

[0014]In another embodiment there is provided a method of decreasing the wound area or volume of a dermal wound including the step of contacting a dermal wound with an effective amount of APC-3K3A, thereby decreasing the wound area or volume of the dermal wound.

[0015]In another embodiment there is provided a method of accelerating the rate of wound healing, or decreasing the time to completion of wound healing or wound closure including the step of contacting a dermal wound with an effective amount of APC-3K3A, thereby accelerating the rate of wound healing, or decreasing the time to completion of wound healing or wound closure.

[0016]In another embodiment there is provided a method of accelerating the rate of wound healing during the first 3 to 7 days, preferably the first 3 to 5 days, preferably the first 3 days following wound formation, including the step of contacting a dermal wound after wound formation with an effective amount of APC-3K3A, thereby accelerating the rate of wound healing. The effective amount of APC-3K3A may be contacted with the dermal wound within 48 hours, preferably within 24 hours or within 12 hours from wound formation. Typically the rate of wound healing is accelerated relative to an untreated wound, or relative to a wound which has been treated with an equivalent amount of APC.

[0018]In another embodiment there is provided a method of minimising inflammation associated with wound repair including the step contacting a dermal wound with an effective amount of APC-3K3A, thereby minimising inflammation associated with wound repair.

Problems solved by technology

A protraction of the wound repair process beyond this time increases the likelihood of formation of a chronic wound.

In particular it has been observed that an absence of inflammation in wound healing is linked with regeneration, whereas presence of inflammation results in some degree of fibrosis and scar formation.

Further, extended inflammation can lead to chronic inflammation, and insofar as cutaneous wounds are concerned, a failure for a wound to properly close, and ulceration.

Images